The reduction of NAIP was not seen in AR− PC-3 prostate tumors (Fig. 4B), further confirming that immunogenic modulation by enzalutamide is strictly dependent upon AR expression (Figs. 1 and 2). The gene discussed is AR; the disease is prostate neoplasm.